ReviewGastro hep advances2026
Glucagon-Like Peptide-1 Receptor Agonists in Inflammatory Bowel Disease: A Narrative Review.
Review in Gastro hep advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have progressed from the initial discovery of endogenous GLP-1 biology in 1986 to widely used therapies for type 2 diabetes and obesity, with expanding indications driven by pleiotropic metabolic and cardiovascular benefits. Although no randomized controlled trials have evaluated GLP-1RA as inflammatory bowel disease (IBD)-directed therapy, retrospective observational studies in IBD populations prescribed GLP-1RA for metabolic indications provide emerging real-world evidence regarding weight loss efficacy, IBD-related outcomes, and adverse events. This narrative review summarizes GLP-1RA pharmacology, mechanistic rationale, and the current clinical evidence base in IBD, with emphasis on safety considerations and priorities for prospective trials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.